These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. EPO in cancer anemia: benefits and potential risks. Milano M; Schneider M Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Henry DH; Abels RI Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Anand A; Anand A; Anand N Cancer; 1996 May; 77(9):1960-1. PubMed ID: 8646701 [No Abstract] [Full Text] [Related]
5. The clinical utility of epoetin in cancer patients: a matter of perspective. Barosi G; Marchetti M Haematologica; 2000 May; 85(5):449-50. PubMed ID: 10800156 [No Abstract] [Full Text] [Related]
6. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer. Henry DH Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671 [TBL] [Abstract][Full Text] [Related]
7. To give or not to give recombinant EPO to anemia endangered cancer patients. Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin treatment of anemic cancer patients. Henry DH Cancer Pract; 1996; 4(4):180-4. PubMed ID: 8900758 [TBL] [Abstract][Full Text] [Related]
9. [Recombinant human erythropoietin in the treatment of the anemia of gynecological tumor patients]. Kurata H; Yoshiya N; Higashino M; Igarashi H; Kaneko T; Kodama S; Tanaka K Gan To Kagaku Ryoho; 1993 Nov; 20(14):2243-5. PubMed ID: 8239694 [No Abstract] [Full Text] [Related]
10. Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy? Taylor SK Med Hypotheses; 2003 Jan; 60(1):89-93. PubMed ID: 12450771 [TBL] [Abstract][Full Text] [Related]
12. Use of recombinant human erythropoietin to treat the anemia of myelodysplastic syndromes. Greenberg PL Semin Hematol; 1993 Oct; 30(4 Suppl 6):22-4. PubMed ID: 8153674 [No Abstract] [Full Text] [Related]
13. [Human recombinant erythropoietin in the treatment of the anemia of multiple myeloma]. Valladares Ayerbes MJ; Valenzuela Claros JC; Reina Zoilo JJ; Ruiz Borrego M; Moreno Nogueira JA An Med Interna; 1997 Nov; 14(11):593-4. PubMed ID: 9445590 [No Abstract] [Full Text] [Related]
14. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin. Barlogie B Semin Hematol; 1993 Oct; 30(4 Suppl 6):25-7. PubMed ID: 8153675 [TBL] [Abstract][Full Text] [Related]
15. Erythropoietin: can we afford to use it? Can we afford not to? Laird J Transfus Med; 2006 Jun; 16(3):204-5. PubMed ID: 16764600 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Desai J; Demetri GD Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913 [TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with anemia of malignancy with recombinant human erythropoietin. Herrmann F; Oster W; Mertelsmann R Contrib Nephrol; 1991; 88():238-45; discussion 246-7. PubMed ID: 2040185 [No Abstract] [Full Text] [Related]
18. Recombinant human erythropoietin and the anemia of multiple myeloma. Barlogie B; Beck T Stem Cells; 1993 Mar; 11(2):88-94. PubMed ID: 8457789 [TBL] [Abstract][Full Text] [Related]
19. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352 [TBL] [Abstract][Full Text] [Related]
20. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]